Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Monthly SOM230C for Recurrent or Progressive Meningioma

15:42 EDT 23rd April 2014 | BioPortfolio

Summary

The purpose of this research study is to evaluate the effectiveness and safety of SOM230C in treating recurrent meningiomas. SOM230C is a newly discovered drug that may stop meningioma cells from growing abnormally. This drug has been used in treatment of other tumors, and information from those other research studies suggests that SOM230C may help to stop the growth of meningiomas.

Description

- To enroll in the study, a sample of the participant's tumor tissue, stored from an earlier study, must be sent to a lab at the Dana-Farber/Harvard Cancer Center for diagnosis and special testing.

- Prior to starting the study medication, participants will undergo a Octreotide scan. This is a special type of scan used to obtain information about certain tumors.

- Participants will receive the study medication, SOM230C, via an injection into the buttocks every 28 days. Therefore, each treatment cycle lasts 28 days.

- The following tests and procedures will be done prior to the first, second and third treatment cycles, and every three treatment cycles thereafter: Complete physical examination including neurological exam; vital signs; current medication and symptom review; EKG; blood samples and a pregnancy test (for women of child-bearing potential).

- In the middle of the first two cycles (around day 15), participants will visit the research doctor for a complete physical examination including a neurological exam and blood work.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Meningioma

Intervention

SOM230C

Location

Cedars-Sinai Medical Center
Los Angeles
California
United States
90048

Status

Recruiting

Source

Dana-Farber Cancer Institute

Results (where available)

View Results

Links

Medical and Biotech [MESH] Definitions

A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)

Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.

Clinical Trials [17 Associated Clinical Trials listed on BioPortfolio]

Biobank Meningioma: Storing Blood for Analysis of DNA and Protein of Patients With Meningioma

The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints which are important for the pat...

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

In this multicenter, Phase II trial, the investigators plan to evaluate the activity of the combination of bevacizumab and everolimus in patients with recurrent, progressive meningioma fol...

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for recurrent glioma and meningioma. PURPOSE: Phase I/II trial to study the eff...

Ph II Imatinib Mesylate + Hydroxyurea in Treatment for Pts w Recurrent/Progressive Meningioma

Primary objective To evaluate activity of imatinib mesylate & hydroxyurea among pts w recurrent meningioma as measured by 6 month progression free survival. Secondary objectives To evalua...

Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma

RATIONALE: Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Specialized radiation therapy that delivers a high dose of radiation d...

PubMed Articles [60 Associated PubMed Articles listed on BioPortfolio]

Primary extracranial meningioma presenting as a cheek mass.

Meningioma is well known as common disease of the central nervous system, whereas primary extracranial meningioma is rare, representing 1% to 2% of all meningiomas. We have experienced a case of prima...

A pilocytic astrocytoma mimicking a clinoidal meningioma.

Pilocytic astrocytomas and meningiomas are benign, primary brain tumors that may involve the optic tract. Classically, the presence of a dural "tail" sign may differentiate a meningioma from other int...

Analysis of a synchronous gliosarcoma and meningioma with long survival: A case report and review of the literature.

The simultaneous occurrence of multiple intracranial neoplasms has been reported, especially in genetic familial syndromes and after cranial irradiation. In the absence of these etiologic factors, som...

Primary extracranial meningioma of paranasal sinuses.

Meningioma is the most common nonglial intracranial neoplasm, arising from meningocytes (arachnoid cap cells) of arachnoid granulation tissue and constitutes 15-20 % of all intracranial tumors. Appro...

Association of methionine synthase rs1801394 and methionine synthase reductase rs1805087 polymorphisms with meningioma in adults: A meta-analysis.

Several epidemiological studies suggested that methionine synthase (MTRR) rs1801394 and methionine synthase reductase (MTR) rs1805087 polymorphisms may be involved in the risk of meningioma in adults;...

More From BioPortfolio on "Monthly SOM230C for Recurrent or Progressive Meningioma"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Trial